Lexaria Bioscience Corp.

Lexaria Bioscience Corp. is a biotechnology company focused on improving how active pharmaceutical ingredients (APIs) are absorbed by the body using its patented DehydraTECH drug delivery technology. DehydraTECH combines APIs with specific long-chain fatty acid-rich triglyceride oils and carrier compounds to enhance their entry into the bloodstream, increasing effectiveness and potentially allowing for lower doses to improve tolerability and promote healthier oral ingestion. The technology is versatile, applicable to a wide range of active molecules including glucagon-like peptide-1 (GLP-1) drugs, glucose-dependent insulinotropic polypeptide (GIP) drugs, vitamins, pain medications, hormones, antivirals, nicotine and its analogs, and cannabinoids. DehydraTECH can be used for various therapeutic indications such as diabetes, weight loss, epilepsy, hypertension, and heart disease. DehydraTECH can be integrated into numerous ingestible product formats, including oral suspensions, tablets, capsules, foods, beverages, and oral pouches. It is suitable for pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The process involves combining an active ingredient with long-chain fatty acid-rich triglyceride oils and infusing this mixture into a carrier substrate material. Through controlled dehydration, the active ingredient and oils are reversibly associated at a molecular level, and these combined molecules are then incorporated into the final product's manufacturing. While the company primarily focuses on pharmaceutical drug products, the technology also extends to nutraceuticals, foods, and beverages. DehydraTECH formulations have sometimes reduced the need for unwanted sweeteners or chemical masking agents used for flavor and odor, allowing for the creation of low-sugar products with fewer calories and artificial sweeteners.